A Phase 3 interventional study of Alma System in Postpartum Haemorrhage (PPH), PPH and Postpartum Hemorrhage (Primary), sponsored by ResQ Medical Ltd. Recruiting at 2 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.
Sponsored by ResQ Medical Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Postpartum Hemorrhage with a site in United States — 10 open to participants now, 12 under way, 3 of them phase 3. Postpartum Hemorrhage · United States.
Among the 65 studies in Postpartum Hemorrhage with a site in United States, this one is the 28th largest by planned enrollment of the 46 interventional ones that give a count, is the only one that started in 2026, is one of 6 in phase 3, reaches primary completion later than 5 of the 11 other live ones, and was the 60th registered.
471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.
Browse Postpartum Hemorrhage studies →10 of the 65 studies in Postpartum Hemorrhage with a site in United States are open now. Recruiting first, the newest first:
Inova Health Care Services · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
Endeavor Health · Sites in United States
Ages 17+ · Women only · Healthy volunteers
Stony Brook University · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Stanford University · Sites in United States
Ages 18–50 · Women only
Holly Ende · Sites in United States
Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 7 · Phase 4 9
First in 2002; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 148 across 362 interventional studies indexed under Postpartum Hemorrhage.
Median enrollment 65 across the 46 interventional studies, 108 across the 18 observational. Of the 50 that completed or were terminated, 24 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 65 have an industry lead sponsor. The 10 most frequent:
ResQ Medical Ltd is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
ResQ Medical Ltd has 2 studies filed under Postpartum Hemorrhage — fewer than ten, so there is no comparison to draw.
8 of the studies in Postpartum Hemorrhage with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06646653Phase 3ResQ Medical LtdEVE TRIAL , ALMA SYSTAM | 2027-01 |
| NCT05245227Phase 3Stony Brook UniversityDouble Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage | 2027-01-01 |
| NCT04146376University of WashingtonVon Willebrand Factor in Pregnancy (VIP) Study | 2026-12 |
| NCT05488457Stanford UniversityOxytocin Pharmacokinetics and Pharmacodynamics | 2026-12-30 |
| NCT06898034Endeavor HealthPostpartum Ultrasound Evaluation to Assess Risk of Hemorrhage | 2027-02-28 |
Add all 8 to your calendar (.ics) → With an account.
Among the 65 studies in Postpartum Hemorrhage with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
abnormal bleeding after childbirth. This condition is called abnormal bleeding and becomes a condition known as postpartum hemorrhage (PPH) when worsens. Abnormal bleeding is defined as the loss of more than 500 milliliters (about two cups) of blood after a vaginal birth, or more than 1,000 milliliters (about four cups) after a cesarean section. It is a serious and potentially life-threatening complication that requires immediate medical treatment.
What you need to know:
Treatment Schedule - Recruitment \& Consenting
Visit 1 - Before Birth (Screening and Enrollment)
No study-related procedures will be done until you have reviewed and signed this consent form. The screening visit tests and procedures are done to see if you are eligible to be in the study. This visit could take a few hours to complete. During this visit, we will collect important background information and perform a physical examination. The following tests and procedures will take place:
Neither you nor your health care plan/insurance carrier will be billed for the collection of the information that will be used for this study.
Visit 2 - Diagnosis and Treatment of Abnormal Bleedong and Post-Partum Hemorrhage (PPH) with the Alma System If you experience abnormal bleeding or postpartum hemorrhage (PPH), your doctor will evaluate all possible causes and follow the hospital's standard treatment protocols. Initial treatment typically includes medications to help the uterus contract and reduce bleeding, as well as manual uterine massage, as recommended by your medical team.
If those treatments do not work, your doctor may decide to use the Alma system to help control or reduce the bleeding.
Once the Alma system is in place, the medical team will perform an ultrasound to check that the device is placed correctly and remains stable.
In addition, the following data will be collected from the treating team:
This will include:
Visit 4 - 6-Week Postpartum Follow-up Examination and Study Completion
A final study follow-up assessment will take place at your routine 6-week postpartum follow-up check-up. The following assessments will be performed:
EBL, determined when investigator is ready to have the Alma peel pack opened:
Vaginal delivery: 500 - 1500 ml EBL or C-section delivery 1000 - 1500 ml EBL
Note: Uterotonic administration may continue concomitantly with and post Alma use, as long as such use does not exceed the maximum dose of the drug 10.3.2 Exclusion Criteria
PPH that the investigator determines to require more aggressive treatment, including any of the following:
Placenta abnormality including any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Woman who developed PPH after vaginal or caesarean delivery and first line interventions have been attempted and failed, and to which the Alma System was applied
Device: Alma System
Subjects diagnosed with abnormal bleeding or postpartum hemorrhage will receive the Alma System. This system comprises a soft silicone cylindrical device placed within the uterus. Gentle suction is applied, prompting the uterus to contract and reduce in size. This contraction compresses the blood vessels, halting the bleeding.
Also known as: Obstetric-gynecologic specialized manual instrument, Vacuum induced heamorrhage control
Incidence of safety events
Incidence, severity and seriousness of device-related Adverse Events (AEs).
Time frame: 6 weeks
PPH control
Control of postpartum hemorrhage, defined as the avoidance of non-surgical, second-line or surgical intervention to control uterine hemorrhage after the use of the Alma System per the Instructions for Use.
Time frame: Procedure
Hemorrhage control
Time to control hemorrhage, defined as the time from turning on the vacuum source until the time the first of any of the following occurs: * there is no blood being collected in the tubing or canister, or * the blood loss is observed as leveled off in the canister, or * blood loss is at a rate of \< 500 ml in 24 hours.
Time frame: minutes to hours
Surgical Intervention
Rate of surgical intervention required to control PPH after Alma use.
Time frame: minutes to hours
Non Surgical intervention
Rate of non-surgical intervention as secondary medications (e.g.uterotonics, pain medications) required to control PPH after Alma use .
Time frame: minutes to hours
Blood product transfusion
Rate of blood product transfusion required after Alma use, and number of transfusion units when administered.
Time frame: hours to days
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.
Of 20 phase 3 interventional studies under Postpartum Hemorrhage, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ResQ Medical Ltd